Free Cardiorenal Forum Autumn webinar
Friday 9th October 2020
12.30 – 14.00 BST (GMT +1)

A practical approach to improving clinical outcomes for patients with cardiorenal disease

What is the webinar about?

This webinar partially replaces some of the topics that would have been discussed at this year’s Annual Scientific Meeting.

Learning objectives

After watching this webinar, participants will:

  • have a better understanding on how to improve outcomes in cardiorenal patients including case studies
  • know more about the use and evidence of benefit of
    • GLP-1 agonists in diabetic nephropathy and cardiovascular patients
    • SGLT2 inhibitors in kidney disease and heart failure
  • have a knowledge of the new agents to modify dyslipidaemia

Is it for me?

This webinar can only be attended by healthcare professionals to whom it is offered free of charge. It is aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, diabetes, care of the elderly, general medicine, general practice, clinical pharmacy and allied disciplines.


The Cardiorenal Forum thanks all of the sponsors - A. Menarini Farmaceutica Internazionale SRL, Astra Zeneca, Bayer, Daiichi-Sankyo, Napp Pharmaceuticals Limited, and Novo Nordisk – for their generous support of this independent webinar. No sponsors have been involved in any of the webinar organisation, content or speaker selection.


The Cardiorenal Forum will issue certificates of attendance – equivalent to 1.5 CPD points (1.5 hours of learning) – after the webinar.

  •   Chairs: Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals NHS Trust
    Professor Philip Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester
  •  12.30 Introduction
  •  12.35 GLP-1 agonists in diabetic nephropathy and cardiovascular patients
    Professor Steve Bain, Professor in Medicine (Diabetes), Swansea University
  •  12.50 SGLT2 inhibitors to protect the kidney?
    Professor David Wheeler, Professor of Kidney Medicine, University College London; Honorary Consultant Nephrologist, Royal Free London NHS Foundation Trust
  •  13.05 SGLT2 inhibitors in patients with heart failure
    Professor Mark Petrie, Professor/Honorary Consultant, Institute of Cardiovascular & Medical Sciences, Glasgow
  •  13.20 Optimising lipid management - a patient centred approach
    Professor Anthony Wierzbicki, Consultant in Metabolic Medicine/Chemical Pathology, Guy’s & St. Thomas’ Hospitals, London; Honorary Professor in Cardiometabolic Disease, King’s College London
  •  13.35 Case presentations with panel discussion
    Ms Jackie Price, Diabetes Specialist Nurse, Salford Royal NHS Foundation Trust; Advanced Nurse Practitioner, Salford Health Care, Part of the Northern Care Alliance NHS Group
  •  13.50 Panel discussion
    Your questions answered by the panel

Professor Steve Bain Professor in Medicine (Diabetes), Swansea University

Steve Bain is Assistant Medical Director for Research and Development for Swansea Bay University Health Board and Clinical Director of the Diabetes Research Unit in Swansea University. After undergraduate training at St John's College, Cambridge, he was clinically trained at King's College Hospital, London. He has worked in London, the East and West Midlands, and West Midlands, and was appointed to a newly created Chair in Medicine (Diabetes) at Swansea University in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Chief Investigator for several multi-centre trials investigating novel therapies for diabetes including ONWARDS, SOUL, PIONEER 6, SUSTAIN 6, and LEADER. He is the Diabetes Lead Clinician for Swansea Bay University Health Board, a member of the Wales Diabetes & Endocrine Society (WEDS) executive committee and chaired the Specialist Training Committee for Diabetes & Endocrinology for Wales until 2016.

Professor Paul Kalra Consultant Cardiologist, Portsmouth Hospitals NHS Trust

Paul Kalra is a Consultant Cardiologist at Portsmouth Hospitals NHS Trust, and an Honorary Professor of Cardiology. His research interests include the role of iron deficiency and its correction in patients with heart failure, cardiorenal disease and the impact of hyperkalaemia on RAAS inhibition use. He is one of the founders of the Cardiorenal Forum and past Chair of the British Society for Heart Failure.

Professor Philip Kalra Consultant Nephrologist, Salford Royal NHS Foundation Trust; Professor of Renal Medicine, University of Manchester

Philip Kalra graduated from Cambridge University and is Professor of Nephrology in Salford and the University of Manchester. He has been a Consultant Nephrologist since 1995, working at the Salford Royal NHS Foundation Trust. He has major research focus on renovascular disease, cardiovascular disease in chronic kidney disease (CKD), CKD progression and iron use in CKD, and he leads the research team in Salford. He was Academic Vice President of the UK Renal Association from 2016–19, Chair of the UK Kidney Research Consortium during this time and was Chair of the NIHR CRN Renal Disorders group from 2010–18. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL and IRONMAN trials, and he has played a role in amalgamating Cardiorenal education and research within the UK.

Professor Mark Petrie Professor/Honorary Consultant, Institute of Cardiovascular & Medical Sciences, University of Glasgow

Mark Petrie worked as a heart failure and interventional cardiologist for many years before transferring to the University of Glasgow in 2016. He was Director of the Scottish National Advanced Heart Failure Service 2010–2014 and has served on the National Advisory Committee for Heart Disease 2004–2018. He established and chaired the Scottish Heart Failure Hub 2014–2017. Mark has published around 130 original manuscripts and has leadership roles in many trials including STICH, REVIVED, REDUCE-LAP, PARADISE-MI, Dapa-HF and IRONMAN. He was an author of the 2011 European Society of Cardiology NSTEMI Guidelines and a reviewer of the 2016 ESC Heart Failure Guidelines.

Ms Jackie Price Diabetes Specialist Nurse, Greater Manchester

Jackie Price is a Diabetes Specialist Nurse at Salford Royal FT and an Advanced Practitioner in Diabetes at Dr Seabrook and Partners in Cheadle Hulme, Stockport. Jackie has extensive clinical experience in managing those with complex diabetes. Jackie has worked in diabetes care for 27 years across primary, secondary and community care in South Manchester and latterly in Salford and she is particularly interested in supporting and developing the management of diabetes in primary care.
She is passionate about sharing skills and knowledge with both patients and healthcare professionals to positively influence the standard of care delivered and make a real difference to the people who live with diabetes.

Professor David Wheeler Professor of Kidney Medicine, University College London, UK and Honorary Consultant Nephrologist, Royal Free London NHS Foundation Trust

David Wheeler trained in Birmingham, Cardiff and Boston, USA. He is interested in chronic kidney disease and its complications, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the design, roll out and monitoring of several large-scale clinical trials. He was a member of the steering committee of SHARP and EVOLVE, and is on the steering committee of CREDENCE, acting as UK principal investigator for this study. He leads the Clinical Research Team in the Centre for Nephrology at the Royal Free Hospital, and is a Past President of the UK Renal Association and Chair of the UK Renal Registry. He has helped develop many guidelines, including Kidney Disease Improving Global Outcome (KDIGO), of which he is co-chair.

Dr Anthony Wierzbicki Consultant in Metabolic Medicine at Guy’s & St Thomas’ Hospital, London

His work in the field of atherosclerosis, which comprises more than 200 publications, has led to appointments as a Fellow of National Association of Clinical Biochemistry (USA) and the American Heart Association (arteriosclerosis and blood pressure sections). He has been a trustee of HEART UK (the UK cholesterol charity) and is a member of many national and international societies. He has sat on many UK government panels in cardiovascular medicine including for the National Institute for Health and Care Excellence. Special interests include, metabolic medicine and chemical pathology, cardiovascular medicine, hyperlipidaemia and obesity.



of delegates said the 2019 meeting was clinically excellent or good


of delegates found the 2019 programme to be good to excellent


of delegates said the 2019 meeting organisation was good to excellent